JPM vs LLY: JPMorgan Chase & and Eli Lilly and compared
The short version
From the latest prices and each company's SEC filings. Who's ahead on each measure, not which to buy.
- Eli Lilly and is the larger company, worth $1.08T, about 1.2 times JPMorgan Chase &.
- Eli Lilly and grew revenue faster over the last year (+47.7% vs +27.7%).
- On earnings, JPMorgan Chase & is the cheaper stock (15.7x vs 43.0x).
Side by side
The stronger figure is shaded where higher (or, for valuation multiples, lower) reads as better. How the implied growth works.
| Measure | JPM | LLY |
|---|---|---|
| Market cap | $878.7B | $1.08T |
| Share price | $332.99 | $1,179.27 |
| Revenue (last fiscal year) | $182.4B | $65.2B |
| Free cash flow (last fiscal year) | — | — |
| Revenue growth, last year | +27.7% | +47.7% |
| Revenue growth per year, last 5 fiscal years | +10.7% | +23.2% |
| Operating margin | — | — |
| Net margin | 32.6% | 33.5% |
| Return on equity | 17.4% | 78.8% |
| P/E (trailing) | 15.7x | 43.0x |
| Price / free cash flow | 8.72x | 120.2x |
| EV / EBITDA | 6.84x | 30.4x |
| FCF growth the price implies | — | — |
| Dividend yield | 1.8% | 0.53% |
| Debt / equity | 12.4x | 3.20x |
| Fundamental grade | B | C |
| Superinvestors holding it | 22 | 12 |
| Insider purchases, last 12 months | 10 | 10 |
Results from SEC filings
Revenue and free cash flow by fiscal year, from each company's 10-K filings.
JPMorgan Chase &
| Year | Revenue | Free cash flow | Op. margin |
|---|---|---|---|
| 2021 | $121.6B | — | — |
| 2022 | $128.7B | — | — |
| 2023 | $158.1B | — | — |
| 2024 | $177.6B | — | — |
| 2025 | $182.4B | — | — |
Eli Lilly and
| Year | Revenue | Free cash flow | Op. margin |
|---|---|---|---|
| 2021 | $28.3B | — | — |
| 2022 | $28.5B | — | — |
| 2023 | $34.1B | — | — |
| 2024 | $45.0B | — | — |
| 2025 | $65.2B | — | — |
Where the revenue comes from
JPMorgan Chase & · by segments, 2025
Commercial & Investment Bank$78.5B44%
Consumer & Community Banking$76.0B43%
Asset & Wealth Management$24.1B13%
Eli Lilly and · by products, 2025
Net product revenue$61.0B94%
Collaboration and Other Revenue$4.2B6%
Compare them in fullFifteen years of statements, quarterly results, DCF and IRR models, and any number of peers side by side.
Open JPM in InvestinglyQuestions
Which is bigger, JPMorgan Chase & or Eli Lilly and?
Eli Lilly and (LLY), at $1.08T against $878.7B.
Is JPM or LLY cheaper?
By trailing P/E, JPMorgan Chase & (15.7x) is cheaper than Eli Lilly and (43.0x). A lower multiple can also mean the market expects less growth.
Which grows faster, JPM or LLY?
Eli Lilly and: revenue grew +47.7% over the last year, against +27.7%.
Prices and ratios as of the last daily update; statements from SEC filings. Information only, not investment advice.